PDF(Pubmed)
Abstract：
Biliary tract cancers (BTCs) are rare and aggressive malignancies with an increasing incidence and poor prognosis. The standard systemic treatment for BTCs has evolved to include immune checkpoint inhibitors associated with gemcitabine-cisplatin as first-line therapies. However, survival rates remain low, highlighting the critical need for personalized treatment strategies based on molecular profiling. Currently, significant advancements have been made in the molecular characterization of BTCs, where genetic alterations, such as IDH1 mutations and FGFR2 fusions, provide targets for therapy. Molecular profiling is crucial early in the management process to identify potential candidates for clinical trials and guide treatment strategy. The integration of these molecular insights into clinical practice has allowed for the development of targeted therapies, although many of them are still in the phase 2 trial stage without definitive survival benefits demonstrated in phase 3 trials. This integration of comprehensive molecular profile insights with traditional treatment approaches offers a new horizon in the personalized medicine landscape for BTCs, with the aim of significantly improving patient outcomes through precision oncology.
摘要：
胆道癌（BTC）是罕见且侵袭性的恶性肿瘤，发病率增加且预后不良。BTC的标准全身治疗已经发展为包括与吉西他滨-顺铂相关的免疫检查点抑制剂作为一线治疗。然而,存活率仍然很低，强调了基于分子谱分析的个性化治疗策略的关键需求。目前,在BTC的分子表征方面取得了重大进展，遗传改变，如IDH1突变和FGFR2融合，为治疗提供靶点。分子谱分析在管理过程的早期至关重要，以确定临床试验的潜在候选者并指导治疗策略。将这些分子见解整合到临床实践中，使得靶向治疗的发展成为可能。尽管他们中的许多人仍处于2期试验阶段，但在3期试验中没有明确的生存获益。这种全面的分子概况见解与传统治疗方法的整合为BTC的个性化医疗领域提供了新的视野。目的是通过精确肿瘤学显着改善患者的预后。
